Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating subcutaneous MK-3222 in moderate-to-severe chronic plaque psoriasis completed; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• MK-3222

Snippet

Sponsor: Sun Pharmaceutical Industries Limited | Conditions: Plaque Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2018-06-13